olokizumab immunomodulator binds interleukin hence acting therapeutic aimed inflammatory disease eg rheumatoid arthritis ra promising results phase ii trial placebo tocilizumab patients moderate severe olokizumab approved medical use russia may russian health ministry approved brand name artlegia olokizumab olokizumab mg used emergence experimental cytokine storm complications phase multicenter placebo activecontrolled trial olokizumab dose mg every weeks superior placebo noninferior adalimumab producing response immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding ithttpsenwikipediaorgwikiolokizumab